Cite
HARVARD Citation
Legrand, F. et al. (2021). A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection. Clinical infectious diseases. pp. e1624-e1631. [Online].